Photo of Baojie  Wan

Baojie Wan


SR RES SPEC, Institute for Tuberculosis Research

Contact

Building & Room:

412

Address:

833 S. Wood Street, Chicago, IL, 60612

Office Phone:

(312) 996-9673

Selected Publications

  • Palmer BD, Sutherland HS, Blaser AG, Kmentova I, Franzblau SA, Wan BM, Wang Y, Ma Z, Denny W, Thompson A. Synthesis and Structure-Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).. Journal of medicinal chemistry. 2015;58(7):3036-59. doi:10.1021/jm501608q.
  • Siricilla S, Mitachi KG, Wan B, Franzblau S, Kurosu M. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors.. The Journal of antibiotics. 2014;. doi:10.1038/ja.2014.133.
  • Ramos Alvarenga RF, Wan B, Inui TG, Franzblau SF, Pauli GU, Jaki B. Airborne antituberculosis activity of Eucalyptus citriodora essential oil.. Journal of natural products. 2014;77(3):603-10. doi:10.1021/np400872m.
  • Pieroni M, Wan B, Cho SG, Franzblau S, Costantino G. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.. European journal of medicinal chemistry. 2014;72:26-34. doi:10.1016/j.ejmech.2013.11.007.
  • Klein L, Petukhova V, Wan B, Wang YD, Santasiero BC, Lankin DF, Pauli GG, Franzblau S. A novel indigoid anti-tuberculosis agent.. Bioorganic & medicinal chemistry letters. 2014;24(1):268-70. doi:10.1016/j.bmcl.2013.11.024.
  • Lv W, Banerjee BL, Molland KN, Seleem MI, Ghafoor A, Hamed MG, Wan BD, Franzblau S, Mesecar A, Cushman M. Synthesis of 3-(3-aryl-pyrrolidin-1-yl)-5-aryl-1,2,4-triazines that have antibacterial activity and also inhibit inorganic pyrophosphatase.. Bioorganic & medicinal chemistry. 2014;22(1):406-18. doi:10.1016/j.bmc.2013.11.011.
  • Ekins SC, Reynolds RG, Franzblau S, Wan BS, Freundlich JA, Bunin B. Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models.. PloS one. 2013;8(5):e63240. doi:10.1371/journal.pone.0063240.
  • Tukulula MJ, Little S, Gut JG, Rosenthal P, Wan B, Franzblau S, Chibale K. The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.. European journal of medicinal chemistry. 2012;57:259-67. doi:10.1016/j.ejmech.2012.08.047.
  • Kunciw DL, Liechty JJ, Mitchell MO, Wan B, Franzblau SG. Structural requirements for the antitubercular quaternized triflupromazine pharmacophore.. Bioorganic & medicinal chemistry letters. 2012;22(17):5679-80. doi:10.1016/j.bmcl.2012.06.095.
  • Dulla B, Wan BG, Franzblau S, Kapavarapu R, Reiser O, Iqbal J, Pal M. Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents.. Bioorganic & medicinal chemistry letters. 2012;22(14):4629-35. doi:10.1016/j.bmcl.2012.05.096.
  • Chopra SA, Koolpe GA, Tambo-Ong AN, Matsuyama KJ, Ryan KB, Tran TS, Doppalapudi RS, Riccio EV, Iyer LE, Green C, Wan BG, Franzblau SB, Madrid P. Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.. Journal of medicinal chemistry. 2012;55(13):6047-60. doi:10.1021/jm300123s.
  • Debnath J, Siricilla SC, Wan BJ, Crick DG, Lenaerts A, Franzblau S, Kurosu M. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.. Journal of medicinal chemistry. 2012;55(8):3739-55. doi:10.1021/jm201608g.
  • Gill SK, Xu HD, Kirchhoff PJ, Cierpicki T, Turbiak AW, Wan BG, Zhang NA, Peng KD, Franzblau S, Garcia G, Showalter H. Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases.. Journal of medicinal chemistry. 2012;55(8):3814-26. doi:10.1021/jm201716n.
  • Lu X, Liu XG, Wan B, Franzblau S, Chen L, Zhou C, You Q. Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.. European journal of medicinal chemistry. 2012;49:164-71. doi:10.1016/j.ejmech.2012.01.007.
  • Chopra SP, Matsuyama K, Tran TG, Malerich JC, Wan BR, Franzblau SB, Lun S, Guo H, Maiga M, Bishai W, Madrid P. Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.. The Journal of antimicrobial chemotherapy. 2012;67(2):415-21. doi:10.1093/jac/dkr449.
  • Blaser AD, Palmer BS, Sutherland HG, Kmentova I, Franzblau SM, Wan BA, Wang Y, Ma Z, Thompson A, Denny W. Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).. Journal of medicinal chemistry. 2012;55(1):312-26. doi:10.1021/jm2012276.
  • Jin YK, Gill SD, Kirchhoff P, Wan BG, Franzblau SA, Garcia GD, Showalter H. Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.. Bioorganic & medicinal chemistry letters. 2011;21(20):6094-9. doi:10.1016/j.bmcl.2011.08.054.
  • Thompson AM, Sutherland HS, Palmer BD, Kmentova IG, Blaser A, Franzblau SA, Wan B, Wang Y, Ma Z, Denny W. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).. Journal of medicinal chemistry. 2011;54(19):6563-85. doi:10.1021/jm200377r.
  • Lu X, Wan BG, Franzblau S, You Q. Design, synthesis and anti-tubercular evaluation of new 2-acylated and 2-alkylated amino-5-(4-(benzyloxy)phenyl)thiophene-3-carboxylic acid derivatives. Part 1.. European journal of medicinal chemistry. 2011;46(9):3551-63. doi:10.1016/j.ejmech.2011.05.018.
  • Macabeo AP, Vidar WS, Chen X, Decker MG, Heilmann JV, Wan BA, Franzblau SA, Galvez E, Aguinaldo M, Cordell G. Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa.. European journal of medicinal chemistry. 2011;46(7):3118-23. doi:10.1016/j.ejmech.2011.04.025.
  • Lu JP, Yuan XH, Yuan HL, Wang W, Wan BG, Franzblau SZ, Ye Q. Inhibition of Mycobacterium tuberculosis methionine aminopeptidases by bengamide derivatives.. ChemMedChem. 2011;6(6):1041-8. doi:10.1002/cmdc.201100003.
  • Hans RH, Wiid IJ, van Helden PD, Wan B, Franzblau SG, Gut JJ, Rosenthal P, Chibale K. Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents.. Bioorganic & medicinal chemistry letters. 2011;21(7):2055-8. doi:10.1016/j.bmcl.2011.02.008.
  • Kmentova IS, Sutherland HD, Palmer BG, Blaser A, Franzblau SA, Wan BM, Wang Y, Ma Z, Denny W, Thompson A. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).. Journal of medicinal chemistry. 2010;53(23):8421-39. doi:10.1021/jm101288t.
  • Pieroni M, Lilienkampf A, Wang YG, Wan BP, Cho S, Franzblau S, Kozikowski A. NOC chemistry for tuberculosis-further investigations on the structure-activity relationships of antitubercular isoxazole-3-carboxylic acid ester derivatives.. ChemMedChem. 2010;5(10):1667-72. doi:10.1002/cmdc.201000169.
  • Mao J, Yuan HG, Wang Y, Wan B, Pak D, He R, Franzblau S. Synthesis and antituberculosis activity of novel mefloquine-isoxazole carboxylic esters as prodrugs.. Bioorganic & medicinal chemistry letters. 2010;20(3):1263-8. doi:10.1016/j.bmcl.2009.11.105.
  • Hans RH, Guantai EM, Lategan CJ, Smith P, Wan BG, Franzblau SJ, Gut J, Rosenthal P, Chibale K. Synthesis, antimalarial and antitubercular activity of acetylenic chalcones.. Bioorganic & medicinal chemistry letters. 2010;20(3):942-4. doi:10.1016/j.bmcl.2009.12.062.
  • Guo S, Song YG, Huang QG, Yuan HP, Wan B, Wang Y, He R, Beconi M, Franzblau S, Kozikowski A. Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents.. Journal of medicinal chemistry. 2010;53(2):649-59. doi:10.1021/jm901235p.
  • Lilienkampf A, Pieroni MG, Wan BP, Wang Y, Franzblau S, Kozikowski A. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.. Journal of medicinal chemistry. 2010;53(2):678-88. doi:10.1021/jm901273n.
  • Sutherland HS, Blaser AG, Kmentova I, Franzblau SD, Wan BA, Wang YM, Ma Z, Palmer B, Denny W, Thompson A. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains.. Journal of medicinal chemistry. 2010;53(2):855-66. doi:10.1021/jm901378u.
  • Palmer BD, Thompson AM, Sutherland HS, Blaser AG, Kmentova I, Franzblau SA, Wan B, Wang Y, Ma Z, Denny W. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).. Journal of medicinal chemistry. 2010;53(1):282-94. doi:10.1021/jm901207n.
  • Mao J, Yuan HB, Wang YP, Wan BG, Pieroni M, Huang Q, van Breemen R, Kozikowski A, Franzblau S. From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters.. Journal of medicinal chemistry. 2009;52(22):6966-78. doi:10.1021/jm900340a.
  • Huang Q, Mao JG, Wan BP, Wang Y, Brun R, Franzblau S, Kozikowski A. Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles.. Journal of medicinal chemistry. 2009;52(21):6757-67. doi:10.1021/jm901112f.
  • Pieroni M, Lilienkampf AG, Wan BP, Wang Y, Franzblau S, Kozikowski A. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.. Journal of medicinal chemistry. 2009;52(20):6287-96. doi:10.1021/jm900513a.
  • Guo SK, Tipparaju SD, Pegan S, Wan B, Mo SD, Orjala JG, Mesecar AP, Franzblau S, Kozikowski A. Natural product leads for drug discovery: isolation, synthesis and biological evaluation of 6-cyano-5-methoxyindolo[2,3-a]carbazole based ligands as antibacterial agents.. Bioorganic & medicinal chemistry. 2009;17(20):7126-30. doi:10.1016/j.bmc.2009.08.061.
  • Zhao YZ, Bacher AE, Illarionov BG, Fischer M, Georg G, Ye Q, Fanwick P, Franzblau S, Wan B, Cushman M. Discovery and development of the covalent hydrates of trifluoromethylated pyrazoles as riboflavin synthase inhibitors with antibiotic activity against Mycobacterium tuberculosis.. The Journal of organic chemistry. 2009;74(15):5297-303. doi:10.1021/jo900768c.
  • Lilienkampf A, Mao JG, Wan BP, Wang Y, Franzblau S, Kozikowski A. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.. Journal of medicinal chemistry. 2009;52(7):2109-18. doi:10.1021/jm900003c.
  • Yuan H, He RF, Wan BG, Wang YP, Pauli G, Franzblau S, Kozikowski A. Modification of the side chain of micromolide, an anti-tuberculosis natural product.. Bioorganic & medicinal chemistry letters. 2008;18(19):5311-5. doi:10.1016/j.bmcl.2008.08.027.
  • Mao J, Eoh HG, He RC, Wang YP, Wan B, Franzblau S, Crick D, Kozikowski A. Structure-activity relationships of compounds targeting mycobacterium tuberculosis 1-deoxy-D-xylulose 5-phosphate synthase.. Bioorganic & medicinal chemistry letters. 2008;18(19):5320-3. doi:10.1016/j.bmcl.2008.08.034.
  • Zhu ZJ, Krasnykh O, Pan D, Petukhova V, Yu GG, Liu H, Hong S, Wang Y, Wan B, Liang W, Franzblau S. Structure-activity relationships of macrolides against Mycobacterium tuberculosis.. Tuberculosis (Edinburgh, Scotland). 2008;88 Suppl 1:S49-63. doi:10.1016/S1472-9792(08)70036-2.
  • Velaparthi S, Brunsteiner MG, Uddin RA, Wan B, Franzblau S, Petukhov P. 5-tert-butyl-N-pyrazol-4-yl-4,5,6,7-tetrahydrobenzo[d]isoxazole-3-carboxamide derivatives as novel potent inhibitors of Mycobacterium tuberculosis pantothenate synthetase: initiating a quest for new antitubercular drugs.. Journal of medicinal chemistry. 2008;51(7):1999-2002. doi:10.1021/jm701372r.
  • Mao J, Wang YP, Wan BG, Kozikowski A, Franzblau S. Design, synthesis, and pharmacological evaluation of mefloquine-based ligands as novel antituberculosis agents.. ChemMedChem. 2007;2(11):1624-30. doi:10.1002/cmdc.200700112.
  • Mao J, Wan BG, Wang YP, Franzblau S, Kozikowski A. HTS, chemical hybridization, and drug design identify a chemically unique antituberculosis agent-coupling serendipity and rational approaches to drug discovery.. ChemMedChem. 2007;2(6):811-3. doi:10.1002/cmdc.200700048.
  • Cho S, Warit S, Wan BH, Hwang CF, Pauli GG, Franzblau S. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.. Antimicrobial agents and chemotherapy. 2007;51(4):1380-5. doi:10.1128/AAC.00055-06.
  • Jayaprakash S, Iso YG, Wan BP, Franzblau S, Kozikowski A. Design, synthesis, and SAR studies of mefloquine-based ligands as potential antituberculosis agents.. ChemMedChem. 2006;1(6):593-7. doi:10.1002/cmdc.200600010.